REMARKS

Applicant acknowledges that claims 1-4, 8-12, 14, 19-21, 23, 28-33, 44, 46, 47, 53-55, 58, 64, 71-74, 77-81, 84, 85, 89, 90, 95, 96, 98, and 100-105 are allowed. However, Applicant requests clarification as to the withdrawn nature of claims 5, 13, 15, 48-52, 56, 57, 65 and 66. These latter claims were withdrawn as not reading on elected species. However the requirement for these species elections clearly states that the claims shall be restricted to the elected species if no generic claim is finally held to be allowable. 35 USC 121. Claim 1 is the generic claim and it is allowed. Accordingly, all claims depending from claim 1, including claims 5, 13, 15, 48-52, 56, 57, 65 and 66, must be considered by the Examiner. 37 CFR 1.141 and 37 CFR 1.146.

Applicant notes that claims 1 and 46 are in no way restricted by the previous species elections, and their scope embraces that of claims 5, 13, 15, 48-52, 56, 57, 65 and 66.

Accordingly, Applicant requests either (a) an acknowledgement that claims 5, 13, 15, 48-52, 56, 57, 65 and 66 are also allowable or (b) that the Examiner search and examine claims 5, 13, 15, 48-52, 56, 57, 65 and 66.

Pursuant to the Examiner's request Applicant also encloses a clean copy of the Manegold et al., Pfizer Poster 2005, Abstract 1131 IDS Citation (#C36) with the attached Information Disclosure Statement.

An action on the merits of all the claims and a Notice of Allowance thereof are respectfully requested.

Respectfully submitted,

Maria A. Trevisan

Registration No.: 48,207

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza 600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000

Date: May 5, 2008

x05.05.08